Navigation Links
Mylan Applauds Signing of Landmark "Food and Drug Administration Safety and Innovation Act"
Date:7/9/2012

PITTSBURGH, July 9, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today applauded President Obama's signing of the "Food and Drug Administration Safety and Innovation Act," landmark legislation that will significantly enhance the safety and security of the U.S. drug supply chain, level the playing field to hold all drug manufacturers to FDA's inspection standards and improve timely access to high quality, affordable generic drugs.  

Mylan CEO Heather Bresch commented, "Mylan has long been a passionate leader and advocate for many of the key provisions included in this important piece of legislation that will help enhance our nation's drug supply chain, and we applaud the extraordinary efforts of the many in Congress who helped craft and pass this vital law in a bipartisan fashion. We believe these important updates to the 1938 law governing FDA will help to protect the health and safety of consumers by globalizing the reach of FDA to reflect today's global pharmaceutical supply chain and ensuring that all drug manufacturing facilities that supply the U.S. market are regularly inspected, regardless of whether they are based inside the U.S. or outside our borders. In particular, I am proud that the generics industry, through the landmark Generic Drug User Fee Act, has stepped up to the plate to help address an industry wide issue by providing FDA with approximately $1.5 billion over five years in order to help fund these increased inspections of drug facilities and ensure faster and more predictable review of generic drug applications."

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com


'/>"/>
SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Launches Thiamine Hydrochloride Injection
2. Mylan Launches Generic Version of Lipitor®
3. Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex®
4. Mylan Announces Settlement Agreement in Patent Infringement Litigation Relating to Sunovions Brovana® Product
5. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
6. Mylan Launches Generic Version of Viramune® Tablets
7. Mylan Sponsors Drug Store News and Pharmacist Society to Provide a New Business Networking Platform for Pharmacy Schools and Students
8. Mylan Launches Generic Version of Plavix® Tablets
9. Mylan Launches Generic Lipitor® in Five European Countries
10. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
11. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American ... function testing company, is now able to perform sophisticated lung assessments ... ndd Medical Technologies , Inc. Patients are no ...  Thanks to ndd,s EasyOne PRO ® , ARL patients like Jeanne ... needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
(Date:6/24/2016)... ... June 24, 2016 , ... Finally, a bruise cream that really works. ... be incorporated into the post-surgical treatment plans of a variety of other procedures including, ... is very effective for bruising and causes a rapid resolution of bruising and inflammatory ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Dr. Seema ... joins Evans Dermatology in the South Lamar location as of July 13, 2016. , ... Medical School. As a medical student, she regularly volunteered at the Agape Clinic serving ...
Breaking Medicine News(10 mins):